Company profile
OSR Holdings, Inc.
NASDAQ: OSRH · Healthcare · Biotechnology
#760 of 1,422 Healthcare companies by revenue29th-percentile growth
EA Score
34DFH 49DQ 12GM —SS 32
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, return on assets · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$1.8M
Rev growth YoY (TTM)
+1627.0%
Net income (FY)
-$27.1M
Employees
22
as of 2026-08-23
Market cap
$9.2M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.9M$2.9M2025
Net income-$27.1M-$27.1M2025
Operating income-$18.3M-$18.3M2025
Total assets$171.2M$171.2M2025
Liabilities$44.2M$44.2M2025
Equity$127.0M$127.0M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is OSR Holdings, Inc.’s revenue?
OSR Holdings, Inc. booked $2.9M in FY2025 revenue, contracting 18% year over year — slower than 71% of Healthcare companies we track, at a -931.2% net margin.
Peers · Healthcare
Xenetic Biosciences, Inc.56CPeakBirch Commerce Inc.——Protara Therapeutics, Inc.43DAmexdrug Corporation69BRadient Technologies Inc.——SCWorx Corp.49DNeighbors
King →Key facts
CEOKuk Hyoun Hwang
SectorHealthcare
IndustryBiotechnology
HeadquartersBellevue, WA
ExchangeNASDAQ: OSRH
Employees22
IPO date2023-03-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.